Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2000
08/08/2000US6100271 Compounds which mediate intracellular signaling response to abnormal external stimuli characteristic of diseases; antiinflammatory agents, antifibrotic agents, antisclerotic agents, antitumor agents
08/08/2000US6100270 Bicyclic heterocyclic compounds for the treatment of impotence
08/08/2000US6100268 Vasoconstrictive dihydrobenzopyran derivatives
08/08/2000US6100267 Enzyme inhibitor for treatment of neurodegenerative disorders, strokes, traumatic brain injury, cataracts
08/08/2000US6100266 Hydroxamic and carboxylic acid derivatives
08/08/2000US6100265 Benzothiopyran and thienothiopyran derivatives; serotonin-2 blocking action; treatment of circulatory diseases in general such as hypertension, ischemic heart disease, cerebrovascular disturbance, and peripheral circulatory disturbance
08/08/2000US6100264 5H, 10H-imidazo [1,2-A] indeno [1,2-E] pyrazin-4-one derivatives, their preparation, their intermediates and medicaments containing them
08/08/2000US6100262 Morpholine ring nitrogen is substituted with a group haivng a carbonyl functionality; favourable gastrointestinal motility stimulating properties, they accelerate gastric emptying
08/08/2000US6100259 Cannabinoid receptor modulators
08/08/2000US6100258 Aromatic amine compounds that antagonize the pain enhancing effects of prostaglandins
08/08/2000US6100256 Orally administering an orally active, long acting, central nervous system-penetrant nk-1(neurokinin-1, substance p) receptor antagonist; for patient who is non-responsive to, or for whom antipsychotic agents are contraindicated
08/08/2000US6100252 Specified compounds including methyl 2-butyl-1-((2'-(2-oxo-3h-1,2,3,5-oxathiadiazol-4-yl)biphenyl) methyl)-benzimidazole-7-carboxylate; use to treat circulatory diseases such as hypertensive diseases and heart diseases
08/08/2000US6100251 Chromium polynicotinate compositions
08/08/2000US6100250 Enteric-coated chromium polynicotinate compositions and uses thereof
08/08/2000US6100249 Use of aspirin for the manufacture of a medicament for implanting an embryo into the uterine endometrium
08/08/2000US6100248 By inhibiting cell proliferation, metastasis; administering 4-de(dimethylamino)tetracycline and specified derivatives; treating cancer of the prostate, breast, and colon, lung melanomas, and lymph cancer
08/08/2000US6100247 Method of treating diabetic neuropathy
08/08/2000US6100246 Spiro-piperidine derivatives as inhibitors of nitric oxide synthase
08/08/2000US6100245 Orally administering simethicone, preferably with sulfasalazine
08/08/2000US6100244 Method for treating respiratory distress by sublingual administration of DNA
08/08/2000US6100243 Method of sensitizing tumor cells with adenovirus E1A
08/08/2000US6100240 Useful as antibacterial agents and antiprotozoa agents
08/08/2000US6100237 Use of des-Aspartate-angiotensin I as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis
08/08/2000US6100234 Treatment of HIV
08/08/2000US6100095 Monitoring metal concentration in blood, cerebral spinal fluid and amniotic fluid; recovering and maintaining sample under aerobic conditions, monitor metal concentration of samples using a preferential ion electrode
08/08/2000US6100090 Compound 8 to 30 nucleobases in length targeted coding region of human phosphatidyl inositol 3'-kinase p85; therapy and diagnosis of diseases related hormone and growth factor receptors and oncogene products
08/08/2000US6100088 Viral vaccines
08/08/2000US6100087 Ribozymes targeted to human CCR5 mRNA
08/08/2000US6100071 Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
08/08/2000US6100059 Compounds
08/08/2000US6099871 Mixture containing waxy grain starch thickener
08/08/2000US6099870 Topical applying agent which inhibits danduff
08/08/2000US6099869 Calcium taurate and antihypertensive drug for hypertension
08/08/2000US6099868 Method of using potassium nitrate for pain reduction
08/08/2000US6099863 Spray drying mixture
08/08/2000US6099862 Oral dosage form for the controlled release of a biguanide and sulfonylurea
08/08/2000US6099860 Tablets; antiinflammatory agent and decongestant
08/08/2000US6099859 Controlled release oral tablet having a unitary core
08/08/2000US6099856 Increased bioavailable
08/08/2000US6099854 Dry composition containing flavonol useful as a food supplement
08/08/2000US6099840 Variant hbsag protein of fragment thereof displaying the antigenicity of hepatitis b virus surface antigen
08/08/2000US6099838 For the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases
08/08/2000US6099837 Pharmaceutical preparation for treating blood coagulation disorders
08/08/2000US6099834 Pharmaceutical compositions and biopesticide compositions
08/08/2000US6099823 Compositions and methods for the treatment and diagnosis of cardiovascular disease
08/08/2000US6099532 Disposable monomer dispenser and vial breaker
08/08/2000US6098631 Compositions and methods for treating autoimmune disease
08/08/2000CA2233144C Arf-p19, a novel regulator of the mammalian cell cycle
08/08/2000CA2212309C Extended-release solid oral dosage forms of drugs having low solubility in water
08/08/2000CA2188227C Combination antiemetic therapy using nk-1 receptor antagonists
08/08/2000CA2188133C Tin-117m-containing radiotherapeutic agents
08/08/2000CA2187402C Quinoxaline derivatives for treating tinnitus
08/08/2000CA2185512C Treatment of tinnitus using neuroprotective agents
08/08/2000CA2185019C Isoxazoline compounds as inhibitors of tnf release
08/08/2000CA2177743C New alkoxy-aryl compounds, process for preparing the same and pharmaceutical compositions containing them
08/08/2000CA2125904C Controlled release formulations coated with aqueous dispersions of ethylcellulose
08/08/2000CA2097695C Biological stain composition, method of preparation and method of use for delineation of epithelial cancer
08/08/2000CA2085796C 3(2h)-pyridazinone derivatives and process for the preparation thereof
08/08/2000CA2072575C Anticholinergic agents
08/08/2000CA2056653C Preparation for transdermal drug administration
08/08/2000CA2027041C Aroyl-ureas
08/08/2000CA2019972C Lipid a analogs having immunoactivating and anti-tumor activity
08/08/2000CA2018438C Imidazolyl-alkenoic acids
08/08/2000CA2017066C Azaindenes
08/08/2000CA2012661C Thienylpiperazines, process for the preparation thereof, the use thereof, and pharmaceuticals containing these and the preparation thereof
08/08/2000CA2012137C Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
08/08/2000CA2010009C Tricyclic fused pyrimidine derivatives, their production and use
08/08/2000CA2000893C Biologically active lipoprotein and its use
08/08/2000CA1341082C Method of treating tumor cells by inhibiting growth factor receptor function
08/08/2000CA1341073C Vectors and methods for expression of human protein c activity
08/05/2000CA2267049A1 Pharmaceutical compositions
08/03/2000WO2000045177A1 Assays for modulators of elongation factor p activity
08/03/2000WO2000045167A2 Non-invasive method for detecting target rna
08/03/2000WO2000045165A1 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
08/03/2000WO2000044906A2 GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)
08/03/2000WO2000044903A1 Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
08/03/2000WO2000044901A1 Transcriptional regulation of the human beta3-adrenergic receptor gene
08/03/2000WO2000044897A1 Method of treating restenosis by antisense targeting of c-myc
08/03/2000WO2000044896A1 Internal ribosome entry site (ires), vector containing same and uses thereof
08/03/2000WO2000044895A1 Method and medicament for inhibiting the expression of a defined gene
08/03/2000WO2000044888A2 Dimethylarginine dimethylaminohydrolases
08/03/2000WO2000044863A1 Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof
08/03/2000WO2000044862A1 Process of converting rendered triglyceride oil from marine sources into bland, stable oil
08/03/2000WO2000044786A1 Novel potassium channels and genes encoding these potassium channels
08/03/2000WO2000044774A2 Inhibition of stat3 signal transduction for human cancer therapy
08/03/2000WO2000044766A1 Inhibition of cationic amino acid transporter protein and uses thereof
08/03/2000WO2000044763A2 Compositions for treating inflammatory response
08/03/2000WO2000044761A2 Ketolide antibiotics
08/03/2000WO2000044757A1 Hesperitin pro-forms with enhanced bioavailability
08/03/2000WO2000044756A1 Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof
08/03/2000WO2000044755A1 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
08/03/2000WO2000044753A1 Pirazino(aza)indole derivatives
08/03/2000WO2000044752A1 Triazolo-pyridazine derivatives as ligands for gaba receptors
08/03/2000WO2000044751A1 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE
08/03/2000WO2000044750A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
08/03/2000WO2000044749A1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
08/03/2000WO2000044748A1 Process for the preparation of alkyl mercapto methyl ergoline derivatives
08/03/2000WO2000044745A1 Carbamate derivatives of diaryl 1,3,4-oxadiazolone
08/03/2000WO2000044744A1 Potassium salt of ($i(s))-omeprazole
08/03/2000WO2000044741A2 Process to prepare cyclic-sulfur fluorine containing oxazolidinones
1 ... 6267 6268 6269 6270 6271 6272 6273 6274 6275 6276 6277 6278 6279 6280 6281 6282 6283 6284 6285 6286 6287 ... 7860